Bret Jensen

Delray Beach

Founder, Biotech Forum and Freelance Columnist at Freelance

Founder @biotech_forum. Get 50% off (regularly $99, yours for $49) from our friends at The Dividend Hunter for your 1st year by clicking https://t.co/9cDlu4SX1I

Featured in: Favicon

msn.com

yahoo.com

fool.com

seekingalpha.com Favicon

thestreet.com (+1) Favicon

thestate.com Favicon

modbee.com Favicon

myrtlebeachonline.com Favicon

theolympian.com Favicon

mercedsunstar.com + 7 more

Articles

The Rebound Is Now Overdone

1 week ago | seekingalpha.com | Bret Jensen

May 04, 2025 8:39 AM ET, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , SummaryMarkets experienced massive volatility in April, with the NASDAQ and Russell 2000 briefly entering bear market territory before snapping back violently later in the month. One month after 'Liberation Day', the markets have done a complete 180 and are back where they were to start April.
The Play On Legend Biotech Stock (NASDAQ:LEGN)

1 week ago | seekingalpha.com | Bret Jensen

May 03, 2025 4:51 AM ET, , , , , , SummaryLegend Biotech's shares have dropped over 60% due to safety and competitive concerns surrounding its sole commercial asset, Carvykti, despite its promising revenue potential. Carvykti, a CAR-T cell therapy for multiple myeloma, has shown strong efficacy but faces supply constraints and upcoming competition from Gilead and Arcellx's anito-cel.
3 Market Predictions For May

2 weeks ago | seekingalpha.com | Bret Jensen

May 01, 2025 12:34 PM ET, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , SummaryAfter going three for three in March with my market predictions, I went two for three in April. I am doubling down on my one missed prediction in April, as yields should move lower as the jobs picture continues to deteriorate.
Talkspace: Making Some Progress (NASDAQ:TALK)

2 weeks ago | seekingalpha.com | Bret Jensen

SummaryToday, we revisit telehealth provider Talkspace, Inc., which offers psychotherapy and psychiatry services to both enterprises and individuals. The company has a rock-solid balance sheet, is seeing north of 20% of annual sales growth, and is becoming more profitable. An updated analysis of TALK stock follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate.
These Two GLP-1 Plays Gained Big, But Are They Buys?

2 weeks ago | pro.thestreet.com | Bret Jensen

Let's look at two stocks in the burgeoning GLP-1 space, why they rallied and how I'd approach each. Remember, GLP-1 drugs are popular for their ability to lower blood sugar levels and to help people lose weight. First is Viking Therapeutics (VKTX) , which was up nearly 8% in trading on Tuesday. The drug-developer's stock also crossed over its 50-day moving average for the first time since late last year. What happened?
Housing Is About To Get Worse

2 weeks ago | seekingalpha.com | Bret Jensen

Apr. 30, 2025 11:30 AM ET, , , , , SummaryHigh mortgage rates and substantial property appreciation in recent years have pushed housing affordability to near historical lows. Existing home sales fell to 30-year lows in 2023 and 2024 and nothing is getting better in 2025. The housing market continues to deteriorate, resulting in large drops in homebuilder stocks over the past few months.
Envista Holdings: A Mixed Picture (NYSE:NVST)

2 weeks ago | seekingalpha.com | Bret Jensen

SummaryToday, we take a deeper look at Envista Holdings Corporation, a dental supply and equipment company. The stock appears to be trying to bottom after a recent decline and despite negative analyst firm opinion on the shares. The company has recently instituted a significant stock buyback program and from a historical perspective, the shares are cheap on a price to sales ratio basis.
Indivior: Trying To Break Addiction (NASDAQ:INDV)

2 weeks ago | seekingalpha.com | Bret Jensen

Apr. 28, 2025 12:12 PM ET, , SummaryIndivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key product franchise, faces competition but shows promise with expanded FDA approval and a stabilizing market share. Despite litigation risks and financial challenges, analysts remain optimistic, projecting growth in the buprenorphine market and potential stock recovery.
'Sell in May and Go Away' Might Just Be Pretty Good Advice

2 weeks ago | pro.thestreet.com | Bret Jensen

Equities staged a large and unexpected rally last week. Despite nominal, at best, progress on new trade deals, stocks went into full risk on mode after a tough start of the week on Monday. By the close of trading on Friday, the Nasdaq had risen 6.7% and the S&P 500 was up 4.6%. This week will mark the close of April and the start of a new month of trading in May.
Buying Into an Industry Pioneer at a Value Price

2 weeks ago | pro.thestreet.com | Bret Jensen

This covered call trade idea centers around an original pioneer in the biotech industry whose stock has fallen around 15% from recent highs amid the overall market pullback. The stock is a good value in a market that I still view as overbought. In addition, the shares sport a solid dividend yield of 3.4%. Like all large pharmaceutical concerns, this company is likely to experience some tariff impacts, albeit less than in many industries within the economy.